摘要
Prevailing evidence declares that Helicobacter pylori (H. pylori) eradication therapycould shift precancerous gastric conditions (PGC) and positively confines gastriccancer (GC) risk during long-term endoscopic follow-up. Nonetheless, there is ayet unsolved controversy regarding the best-individualized surveillance strategiesfollowing H. pylori eradication, based on malignant risk stratification. This lastdispute is due to the uncertainty of contemporary evidence and the role of H.pylori inflammatory changes in underestimating PGC at the index endoscopy.However, the current state of the art suggests that it is reasonable that highqualityendoscopy with histological assessment for the most accurate diagnosis ofPGC may be delayed in selected high-risk patients without alarm signs formalignancy, following the eradication of H. pylori. Notwithstanding, these aspectsneed to be further examined in the next future to establish and optimize the mostbeneficial and cost-effective strategies for recognizing and managing H. pyloripositivepatients with PGC in the short- and long-term follow-up. Accordingly,additional studies are yet required to sharpen the hazard stratification of patientswith the greatest chance of GC evolution, also recognizing the evolving racial,ethnic, immigration factors and the necessity of novel biomarkers to limit GCdevelopment or accomplish a diagnosis of malignancy at an early stage.
